Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Predicting safety and success of reinitiation of infliximab therapy

Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy, reports the latest issue of the Clinical Gastroenterology & Hepatology.

News image

Few agents are available for the treatment of inflammatory bowel diseases, and patients frequently become unresponsive to biologics.

Dr Filip Baert and colleagues from Belgium investigated the feasibility of reinitiating infliximab therapy for patients who previously received only episodic therapy with, lost response to, or had infusion reactions to infliximab.

The researchers identified factors associated with the success and safety of restarting infliximab, such as antibodies to infliximab and trough levels of the drug.

From the inflammatory bowel disease biobank, the team identified 128 consecutive patients who restarted infliximab after a median 15-month discontinuation.

The researchers also analyzed serum samples that had been collected during the first period of infliximab therapy, when therapy was reinitiated, and at later time points for trough levels and antibodies to infliximab.

15 patients had acute infusion reactions
Clinical Gastroenterology & Hepatology

The team investigated correlations among response to treatment, infusion reactions, treatment modalities, trough levels, and antibodies to infliximab.

Reinitiation of infliximab therapy produced a response in 84.5% of patients at week 14, 70% of patients at 1 year, and in 61% of patients at more than 4 years.

The research team found that 15 patients had acute infusion reactions, and 10 patients had delayed infusion reactions.

The absence of antibodies to infliximab at T+1 and reinitiation with concomitant immunomodulator therapy were associated with short-term responses.

The team noted that pregnancy or remission as reason for discontinuation, and higher trough levels at T+1 were associated with long-term response.

Undetectable antibodies to infliximab at T+1 were associated with the safety of reinitiating therapy HR for infusion reaction with detectable antibodies to infliximab.

Dr Baert's team concludes, "Reinitiating infliximab therapy can be safe and effective for patients with Crohn's disease or ulcerative colitis after a median 15-month discontinuation period."

Clin Gastroenterol Hepatol 2014: 12(9): 1474–1481.e2
03 September 2014

Go to top of page Email this page Email this page to a colleague

 20 December 2014

Advanced search
 19 December 2014 
Idiopathic inflammatory demyelinating disease in IBD
 19 December 2014 
Colorectal cancer risk for first-degree relatives
 19 December 2014 
Thiopurine treatment and colectomy in ulcerative colitis
 18 December 2014 
Assessment of Crohn's disease activity
 18 December 2014 
Vitamin D and sustained virologic response in HCV
 18 December 2014 
Factor for treatment in IBS
 17 December 2014 
Non-invasive measures of fatty liver
 17 December 2014 
Remission from hepatic encephalopathy with rifaximin
 17 December 2014 
Colonic adenoma recurrence after endoscopic resection
 16 December 2014 
Screening esophagus during routine US
 16 December 2014 
Therapeutic targets in IBD
 16 December 2014 
Diagnostic tool for dysplasia in Barrett's
 15 December 2014 
Esophageal adenocarcinoma and Barrett's
 15 December 2014 
Outcomes of mildly abnormal liver function tests
 15 December 2014 
Food allergy and food intolerances
 12 December 2014 
Hospital readmission after colorectal resection
 12 December 2014 
Detecting intestingal damage in Crohn's
 12 December 2014 
SSRIs for noncardiac chest pain
 11 December 2014 
Hep C and post-liver transplant diabetes
 11 December 2014 
Antiviral therapy and post-hepatectomy survival
 11 December 2014 
Barrett’s risk factors in African Americans vs Non-Hispanic Whites
 10 December 2014 
Prompt endoscopy for uninvestigated dyspepsia
 10 December 2014 
Microbiota composition on gluten-free diet in celiac disease
 10 December 2014 
Utilization of health care resources in ileostomy patients
 09 December 2014 
Diverticular disease and irritable bowel syndrome
 09 December 2014 
Management of acute colonic diverticulitis
 09 December 2014 
Food intolerance
 08 December 2014 
Portal vein obstruction
 08 December 2014 
Readmission after restorative proctocolectomy with IPAA
 08 December 2014 
Metachronous colorectal cancer
 05 December 2014 
Esophageal cancer in Veterans with Barrett’s esophagus
 05 December 2014 
Clinical outcome in pediatric Crohn's
 05 December 2014 
Hepatocellular carcinoma surveillance survey
 04 December 2014 
Diagnosis of NAFLD and NASH
 04 December 2014 
Ethnic disparities in gastric cancer
 04 December 2014 
Gilbert's syndrome and respiratory health
 03 December 2014 
Unmet treatment needs of GERD
 03 December 2014 
Finding sessile serrated adenomas during colonoscopy
 03 December 2014 
Antibiotics in acute uncomplicated diverticulitis
 02 December 2014 
Vit D and sustained virologic response in Hep C
 02 December 2014 
Severe esophagitis and upper GI bleeding
 02 December 2014 
Critical illness in patients with IBD
 01 December 2014 
Algorithms for the diagnosis of Lynch syndrome
 01 December 2014 
Differentiates inflammatory from functional intestinal disorders
 01 December 2014 
Racial disparities in colorectal cancer survival
 28 November 2014 
C. diff and pediatric IBD
 28 November 2014 
Fruit and vegetable consumption and esophageal cancer
 28 November 2014 
IBD and students' adjustment to college
 27 November 2014 
Prediction of functional GI disorders later in life
 27 November 2014 
Differences in the incidence of esophageal adenocarcinoma
 27 November 2014 
End points of outcomes in primary biliary cirrhosis
 26 November 2014 
Detection of gastric precancerous conditions
 26 November 2014 
Vegetables and garlic and colorectal cancer risk
 26 November 2014 
Fertility in women with celiac disease
 25 November 2014 
Esophagogastric junction of children with GERD
 25 November 2014 
Symptom activity index for eosinophilic esophagitis
 25 November 2014 
Placebo response rate in fistulizing Crohn's
 24 November 2014 
Nasoenteric tube feeding in acute pancreatitis
 24 November 2014 
Corticosteroids and infections in elderly-onset IBD
 24 November 2014 
Adhesions in abdominal and pelvic surgery

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us